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The present study aimed to directly characterize speciﬁc binding sites of tritium ([3H])-labeled imida-
fenacin, a new radioligand for labeling muscarinic receptors, in the bladder and other peripheral or
central nervous tissues of rats.
Muscarinic receptors in rat tissues were measured by radioligand binding assay using [3H]
imidafenacin.
Speciﬁc [3H]imidafenacin binding in rat tissues was saturable, reversible, and of high afﬁnity. Esti-
mated dissociation constants (Kd values) were signiﬁcantly lower in submaxillary gland and prostate and
higher in heart than in bladder, indicating lower Kd values in M1 and M3 subtype- than M2 subtype-
dominating tissues. Unlabeled imidafenacin and clinically used antimuscarinic agents competed with
[3H]imidafenacin for binding sites in bladder and other tissues in a concentration-dependent manner,
which indicated pharmacological speciﬁcity of [3H]imidafenacin binding sites. Pretreatment with N-(2-
chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard), an irreversible inactivating agent of M3
subtype, signiﬁcantly decreased the number of [3H]imidafenacin binding sites in bladder, submaxillary
gland, and colon, but not in heart. [3H]imidafenacin labeled muscarinic receptors in M1 and M3 subtype-
dominating tissues with higher afﬁnity than [N-methyl-3H]scopolamine methyl chloride (NMS).
[3H]imidafenacin is a useful radioligand to label muscarinic receptors in M1- and M3-dominating
tissues with high afﬁnity.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Overactive bladder (OAB) is characterized by an increased fre-
quency of micturition, urgency, and urge incontinence, and nega-
tively affects the quality of life of many elderly people (1)., [N-methyl-3H]scopolamine
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d/4.0/).Pharmacological treatments with antimuscarinic agents have been
the main stay of therapy for patients with OAB (2,3). The efﬁcacy of
these drugs is known to be mediated through the blockade of
muscarinic receptors in the bladder urothelium and detrusor
muscle (4). However, antimuscarinic agents have also been asso-
ciated with systemic adverse effects in patients with OAB, which
have been attributed to signiﬁcant binding to muscarinic receptors
in organs other than the bladder (5,6). The most frequent adverse
effect of antimuscarinic agents, dry mouth, was shown to be mainly
due to the blockade of muscarinic receptors in the salivary gland.
Imidafenacin (4-(2-methyl-1H-imidazol-1-yl)-2,2,diphenylbu-
tanamide, KRP-197/ONO-8025) is an antimuscarinic agent that is
used to treat OAB in Japan. A previous study demonstrated that itnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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receptor subtype (7), which allowed it to regulate the release of
acetylcholine by inhibiting the prejunctional M1 subtype and also
inhibit bladder contraction by blocking the postsynaptic M3 sub-
type. Further studies revealed that imidafenacin exhibited func-
tional selectivity toward the bladder over the salivary gland and
had a negligible pharmacological effect on the CNS, even at high
doses (8,9). Imidafenacin is a well-tolerated agent in clinical set-
tings and causes fewer adverse effects (10,11). Masumori (12),
Takeuchi (13), and Maggiore (14) reviewed the long-term efﬁcacy,
safety, and tolerability of imidafenacin, and reported a reduced
incidence of adverse events, such as dry mouth and constipation.
Furthermore, imidafenacin is safe for long-term use, even by
cognitively vulnerable elderly patients with the symptoms of OAB.
Thus, imidafenacin is a safe, efﬁcacious, and tolerable agent that has
the ability to control the symptoms of OAB, even in the long term.
We previously examined the competitive inhibitory effects of
imidafenacin on [N-methyl-3H]scopolaminemethyl chloride (NMS)
binding and revealed that it was a potent inhibitor of muscarinic
receptor binding sites in the bladders of rats and humans (15). The
aim of the present study was to directly characterize the binding
properties of tritium ([3H])-labeled imidafenacin ([3H]imidafena-
cin) with highly speciﬁc activity in the bladder and other peripheral
or central nervous tissues, in terms of the pharmacological use-
fulness of this radioligand.
2. Materials and methods
2.1. Materials
[3H]Imidafenacin (4-(2-methyl-1H-imidazol-1-yl)-2-phenyl-2-
(3-tritiophenyl)-butanamide) (851 GBq/mmol) and imidafenacin
were donated by Kyorin Pharmaceutical Co., Ltd. (Tokyo). Oxy-
butynin hydrochloride, solifenacin succinate, and tolterodine L-
tartrate were donated by Meiji Milk Products Co., Ltd. (Odawara),
Astellas Pharma Inc. (Tokyo), and Pﬁzer Co., Ltd. (Tokyo), respec-
tively. All other chemicals were purchased from commercial
sources.
2.2. Animals
Male SpragueeDawley rats (250e300 g) at 8e10 weeks of age
were purchased from Japan SLC (Shizuoka, Japan). They were
housed in the laboratory with free access to food and water and
maintained on a 12-h lightedark cycle in a roomwith a controlled
temperature (24 ± 2 C). Animal care and experiments were per-
formed in accordance with the guidelines for the care and use of
laboratory animals of the University of Shizuoka (registration
number: 136037).
2.3. Tissue preparation and radioligand binding assay of [3H]
imidafenacin
Rats were sacriﬁced by taking blood from the descending aorta
under anesthesia with pentobarbital sodium (50 mg/kg, i.p.). Pe-
ripheral (bladder, submaxillary gland, heart, colon, lung, and
prostate) and central nervous (cerebral cortex, hippocampus,
corpus striatum, thalamus, pons/medulla oblongata, midbrain, and
cerebellum) tissues were dissected, minced carefully with scissors,
and homogenized using a Kinematica Polytron homogenizer in 19
volumes of ice-cold 30 mM Naþ/HEPES buffer (pH 7.5). The ho-
mogenate was centrifuged at 40,000  g for 20 min. The pellet was
suspended in the same buffer for the binding assay. Protein con-
centrations were measured using the BCA Protein Assay Kit
(Thermo scientiﬁc, Rockford, IL).In saturation binding experiments with [3H]imidafenacin, the
tissue homogenates of rats were incubated with various concen-
trations (0.5e8.0 nM) of [3H]imidafenacin in 30 mM Naþ/HEPES
buffer (pH 7.5) at 25 C for 60 min at a total assay volume of 1 mL
(14). In competition binding experiments, the tissue homogenate
(3.0 mg of original tissue) was incubated with [3H]imidafenacin
(4.0 nM) in the presence of each antimuscarinic agent at 25 C for
60 min. The reaction was terminated by rapid ﬁltration (Cell
Harvester; Brandel Co, Gaithersburg, MD, USA) through Whatman
GF/B glass ﬁlters. The ﬁlters were then rinsed three times with 3mL
of ice-cold 50 mM Naþ/Kþ phosphate buffer (pH 7.4). Tissue-bound
radioactivity was extracted from the ﬁlters overnight by immersion
in scintillation ﬂuid [2 L toluene, 1 L Triton X-100, 15 g of 2,5-
diphenyloxazole, and 0.3 g of 1,4-bis[2-(5-phenyloxazolyl)]ben-
zene], and radioactivity was determined using a liquid scintillation
counter (LSC-7400, Hitachi-Aloka Medical, Tokyo, Japan). Speciﬁc
[3H]imidafenacin binding was determined experimentally from the
difference between these counts in the absence and presence of
1 mM atropine.
In the kinetics study, [3H]imidafenacin binding (4.0 nM) was
quantiﬁed as a function of time for 60 min from the addition of the
ligand, and the dissociation of the [3H]imidafenacin-receptor
complex was then monitored by the addition of 0.1 mM atropine.
In experiments in which N-(2-chloroethyl)-4-piperidinyl
diphenylacetate (4-DAMP mustard) was used, the compound
was ﬁrst incubated at 37 C for 30 min in Krebs-Ringer bicar-
bonate (124 mM NaCl, 5 mM KCl, 1.3 mM MgSO4, 26 mM NaHCO3,
1.2 mM KH2PO4, 1.8 mM CaCl2, and 10 mM glucose) (KRB) buffer,
pH 7.4, in order to allow the formation of reactive aziridinium ions
(cyclized 4-DAMP mustard) (16,17). The tissue homogenate was
carefully prepared using KRB buffer as described previously. It
was then incubated with 1 mM AF-DX116 at 37 C for 10 min to
reversibly block M2 receptors. This was followed by the addition
of 10 nM cyclized 4-DAMP mustard, and the homogenate was
incubated at 37 C for 60 min to irreversibly block M3 receptors.
The reaction was stopped by an incubation with 1 mM sodium
thiosulfate for 15 min. The homogenate was then centrifuged at
40,000  g for 10 min and the resulting pellet was ﬁnally resus-
pended in KRB buffer for the binding study. All steps were per-
formed at 4 C.
The binding assay for muscarinic receptors in rat tissues was
also performed using [N-methyl-3H]scopolamine methyl chloride
([3H]NMS), which has been commonly used as a radioligand to
measure muscarinic receptor binding, as described previously
(18,19). All assays were conducted in duplicate.
2.4. Data analysis
[3H]Imidafenacin binding data were subjected to a non-linear
regression analysis using Graph Pad PRISM (ver. 4, Graph Pad
Software, San Diego, CA). The apparent dissociation constant (Kd)
and maximal number of binding sites (Bmax) for [3H]imidafenacin
were estimated. The rate constants of association (kþ1) and disso-
ciation (k1) from the association and dissociation experiments
were also estimated (20). The ability of nonlabeled agents to inhibit
speciﬁc [3H]imidafenacin (4.0 nM) binding was estimated from the
IC50, which is the molar concentration of each agent needed to
displace 50% of speciﬁc [3H]imidafenacin binding. The inhibition
constant, Ki, was calculated from the equation, Ki ¼ IC50/(1 þ L/Kd),
where L represents the concentration of [3H]imidafenacin.
Statistical analyses of receptor binding data were performed
with the Student's t-test and a one-way analysis of variance
(ANOVA), followed by Dunnett's test for multiple comparisons. All
data are expressed as the mean ± S.E.M. Signiﬁcance was accepted
at P < 0.05.
Table 1
Kd and Bmax for speciﬁc binding of [3H]imidafenacin in rat peripheral tissues.
[3H]Imidafenacin
Kd (nM) Bmax (fmol/mgprotein)
Bladder 1.25 ± 0.18 372 ± 24
Submaxillary gland 0.44 ± 0.03*** 177 ± 10
Heart 4.54 ± 0.62*** 140 ± 17
Colon 1.40 ± 0.24 300 ± 27
Lung 1.32 ± 0.47 51 ± 15
Prostate 0.53 ± 0.16* 103 ± 18
The speciﬁc binding of [3H]imidafenacin (0.25e8.0 nM) in rat peripheral tissues was
measured in the absence and presence of 1 mMatropine. Asterisks show a signiﬁcant
difference from bladder values, *P < 0.05, ***P < 0.001 (the Student's t-test). Each
value represents the mean ± S.E.M. of four to seven rats.
Table 2
Kd and Bmax for speciﬁc binding of [3H]imidafenacin in the rat brain.
[3H]Imidafenacin
Kd (nM) Bmax (fmol/mg protein)
Cerebral cortex 0.87 ± 0.07 1582 ± 105
Hippocampus 0.93 ± 0.08 1556 ± 101
Corpus striatum 0.96 ± 0.08 2344 ± 143
Thalamus 0.83 ± 0.08 750 ± 92
Pons/medulla oblongata 1.95 ± 0.08 436 ± 34
Midbrain 1.50 ± 0.11 781 ± 108
Cerebellum 2.94 ± 0.34 195 ± 15
The speciﬁc binding of [3H]imidafenacin (0.25e8.0 nM) in the rat brain was
measured in the absence and presence of 1 mM atropine. Each value represents the
mean ± S.E.M. of four to six rats.
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3.1. Identiﬁcation of speciﬁc [3H]imidafenacin binding in the
bladder and other tissues of the rat
The speciﬁc binding of [3H]imidafenacin was measured at
various concentrations (0.3e8.0 nM) in homogenates of the rat
bladder and other tissues. The speciﬁc binding of [3H]imidafenacin
was saturable, forming a plateau at approximately 4.0 nM (bladder)
of [3H]imidafenacin; however, nonspeciﬁc binding increased line-
arly with an increase in [3H]imidafenacin concentrations (Fig. 1).
The estimated Kd value for [3H]imidafenacin in the bladder was
1.25 ± 0.18 nM and the Bmax value was 372 ± 24 fmol/mg protein
(mean ± S.E.M., n ¼ 7).
As shown in Tables 1 and 2, the dissociation constant (Kd) of [3H]
imidafenacin was lower in the submaxillary gland, prostate, cere-
bral cortex, hippocampus, corpus striatum, and thalamus
(0.4e1.0 nM) than in the heart (4.54 nM) and cerebellum (2.94 nM),
and was intermediate in the bladder, colon, lung, pons/medulla
oblongata, andmidbrain (1.3e2.0 nM). The Kd values of speciﬁc [3H]
imidafenacin binding were signiﬁcantly lower in the submaxillary
gland and prostate and higher in the heart than in the bladder
(Table 1). In central nervous tissues, the Bmax value of [3H]imida-
fenacin was the highest in the corpus striatum, followed by the
cerebral cortex, hippocampus, midbrain, thalamus, pons/medulla
oblongata, and cerebellum (Table 2). Kd values were similar
(1e2 nM) among these tissues, except for that in the cerebellum
(2.94 nM). A tissue differencewas observed in the Kd of speciﬁc [3H]
imidafenacin binding; however, differences in the Kd values
(0.2e0.3 nM) of speciﬁc [3H]NMS binding were negligible among
the peripheral and central nervous tissues of the rat (data not
shown). On the other hand, a strong correlation was noted in Bmax
values in peripheral or central nervous tissues between [3H]imi-
dafenacin and [3H]NMS (Fig. 2). The Kd values of [3H]NMS in these
peripheral or central nervous tissues were approximately
0.2e0.3 nM (data not shown).
As shown in Fig. 3A, [3H]imidafenacin rapidly associated with its
binding sites in the bladder, submaxillary gland, and heart of the
rat, reached an equilibrium by 10 min, and remained at a steady
state until at least 60 min. Binding was rapidly dissociated by the
addition of 0.1 mM atropine (Fig. 3B). The rate constants for the
association (kþ1) and dissociation (k1) of [3H]imidafenacin in the
rat bladder were calculated as 7.85 ± 0.12  107 M1 min and
1.54 ± 0.22  101 min, respectively. The rate constants for the
association (kþ1) and dissociation (k1) of [3H]imidafenacin in the
submaxillary gland were calculated as 17.3 ± 1.6 107 M1,min and
0.45 ± 0.02  101 min, respectively. Thus, the dissociationFig. 1. (A) Total (B), speciﬁc (C), and nonspeciﬁc (▵) binding in the rat bladder andconstants (Kd ¼ k-1/kþ1) for the [3H]imidafenacin receptor inter-
action were estimated to be 1.96 and 0.26 nM, respectively. These
kinetic Kd strongly correlated with Kd estimated from saturation
studies (Table 1).3.2. Inhibition of speciﬁc [3H]imidafenacin binding by
antimuscarinic agents
Antimuscarinic agents such as atropine, imidafenacin, tolter-
odine, oxybutynin, solifenacin concentration-dependently inhibi-
ted speciﬁc [3H]imidafenacin binding in the bladder and other
tissues (Fig. 4). Based on the Ki values, imidafenacin, tolterodine,
and atropine displayed relatively higher afﬁnity to bladder [3H]
imidafenacin binding than oxybutynin and solifenacin (Table 3). In
the bladder, the rank order of these agents in terms of afﬁnity for
[3H]imidafenacin binding sites was atropine > imidafenacin,
tolterodine > oxybutynin > solifenacin. The muscarinic binding(B) its Scatchard analysis. Each point represents the mean ± S.E.M. of seven rats.
Fig. 2. Relationship between Bmax values of the speciﬁc binding of [3H]imidafenacin (Tables 1 and 2) and [3H]NMS in peripheral tissues (A) and central nervous tissues (B). Each
point represents the averaged value. Pearson's correlation coefﬁcient for this relationship was Pearson's r ¼ 0.96 (peripheral tissues) and 0.98 (central nervous tissues).
S. Kuraoka et al. / Journal of Pharmacological Sciences 131 (2016) 184e189 187afﬁnity of imidafenacin in the bladder was approximately 20-fold
higher than that of solifenacin.
3.3. Effects of 4-DAMP on muscarinic receptors
In order to characterize [3H]imidafenacin binding sites in rela-
tion to the relative distribution of M2 and M3 muscarinic receptorFig. 3. Time course of the association (A) and dissociation (B) of speciﬁc [3H]imida-
fenacin binding in the bladder, submaxillary gland, and heart of rats. [3H]Imidafenacin
binding in each tissue was quantiﬁed as a function of time from its addition. [3H]
Imidafenacin-receptor complexes in each tissue were also monitored by the addition of
0.1 mM atropine after a 60 min-incubation with [3H]imidafenacin. Each point repre-
sents the mean ± S.E.M. of four to eight rats.subtypes in rat tissues, speciﬁc [3H]imidafenacin binding was
examined by a pretreatment with 4-DAMPmustard, an irreversible
inactivating agent of the M3 subtype (6,16). The treatment with 4-
DAMP mustard led to signiﬁcant decreases (45%, 84%, 21% and 1%,
respectively) in the Bmax values for speciﬁc [3H]imidafenacin
binding in the bladder, submaxillary gland, colon, and heart from
control values (Table 4). On the other hand, no signiﬁcant change
was observed in the Kd values for speciﬁc [3H]imidafenacin binding
by the 4-DAMP treatment.4. Discussion
Imidafenacin was previously shown to be a well-tolerated
therapeutic agent for OAB with few adverse effects (10,12e14).
We previously demonstrated that imidafenacin bound muscarinic
receptors in the bladders of rats and humans with high afﬁnity by
characterizing the inhibitory effects of imidafenacin on the speciﬁc
binding of [3H]NMS, the most commonly used radioligand of
muscarinic receptors (9,15).
The present study directly characterized the speciﬁc binding
sites of novel tritium ([3H])-labeled imidafenacin ([3H]imidafena-
cin) with highly speciﬁc activity in the bladder and other tissues of
the rat. A signiﬁcant level of speciﬁc binding of [3H]imidafenacin
was observed in rat tissues, and binding was saturable, reversible,
and of high afﬁnity, as shown by the nanomolar range of Kd values
in the bladder and other tissues of the rat (Table 1). The estimated
values of Kd and Bmax in the rat bladder were 1.25 nM and 372 fmol/
mg protein, respectively. Furthermore, based on the association and
dissociation of speciﬁc [3H]imidafenacin binding in rat tissues
(Fig. 3), the kinetic dissociation constant (Kd ¼ k1/kþ1) for the [3H]
imidafenacin receptor interaction in the bladder and submaxillary
gland strongly correlated with Kd estimated from saturation
studies. The Bmax values of speciﬁc [3H]imidafenacin binding in rat
peripheral and central nervous tissues were similar to those for
speciﬁc [3H]NMS binding (Fig. 2).
Our previous studies with muscarinic M1eM5 receptor single
knockout mice clearly showed that the relative distribution of
muscarinic receptor subtypes (M1eM5) differed signiﬁcantly
among peripheral and/or central nervous tissues (21,22). The sali-
vary gland predominantly contains M3 muscarinic receptors
(6,17,22e24), whereas the bladder contains both the M2 and M3
subtypes, with a predominance of M2 receptors (22,25). Further-
more, the expression of the M3 subtype was higher in the salivary
gland than in the bladder (22). Maruyama et al. (26) suggested that
Fig. 4. Competitive inhibition of speciﬁc [3H]imidafenacin binding in the bladder, submaxillary gland, colon, and cerebral cortex by four to six concentrations of antimuscarinic
agents (C: atropine,B: imidafenacin,:: tolterodine,△: oxybutynin,-: solifenacin). The concentration of [3H]imidafenacin was 4 nM (bladder) or 2 nM (submaxillary gland,
colon, and cerebral cortex). The abscissa is the logarithmic molar concentration of antimuscarinic agents. The ordinate is speciﬁc [3H]imidafenacin binding (% of control). Each point
represents the mean ± S.E.M. of four to ﬁve rats.
Table 4
Effects of 4-DAMP mustard on Kd and Bmax of speciﬁc binding of [3H]imidafenacin in
peripheral tissues of rats.
Kd (nM) Bmax (fmol/mg protein)
S. Kuraoka et al. / Journal of Pharmacological Sciences 131 (2016) 184e189188the human parotid gland predominantly contains the M3 subtype
based on the results of [3H]NMS binding assays with human tissue
and the membranes of CHO-K1 cell lines expressing the human
M1eM5 receptor subtypes. Imidafenacin was previously shown to
exhibit greater selectivity for the M1 and M3 subtypes than the M2
subtype in CHO-K1 cells expressing human muscarinic receptors
(7) and human tissues (15, 17), and the high afﬁnity of [3H]imida-
fenacin for muscarinic receptors in the human parotid gland re-
ﬂected M3-subtype selectivity (27).
In the present study, the dissociation constant (Kd) of [3H]imi-
dafenacin was lower in rat tissues (submaxillary gland, prostate,
cerebral cortex, hippocampus, corpus striatum, and thalamus)
predominantly containing M1 and M3 receptors than in M2
receptor-dominating tissues (heart and cerebellum), and was in-
termediate in their coexisting tissues (bladder, colon, lung, pons/
medulla oblongata, and midbrain) (Tables 1 and 2). The Kd values ofTable 3
Ki values for speciﬁc binding of [3H]imidafenacin in rat tissues.
Bladder Submaxillary gland Colon Cerebral cortex
Ki (nM) Ki (nM) Ki (nM) Ki (nM)
Atropine 0.26 ± 0.03 0.46 ± 0.04 1.24 ± 0.23 0.37 ± 0.01
Imidafenacin 1.25 ± 0.24 0.58 ± 0.03 1.43 ± 0.22 0.96 ± 0.07
Tolterodine 1.85 ± 0.48 2.55 ± 0.39 2.18 ± 0.39 1.39 ± 0.11
Oxybutynin 11.0 ± 1.1 4.11 ± 0.61 16.9 ± 2.2 3.78 ± 0.34
Solifenacin 25.1 ± 4.8 18.7 ± 2.4 36.3 ± 5.3 16.9 ± 1.6
The inhibition of speciﬁc [3H]imidafenacin (4.0 nM) binding in rat tissues by anti-
muscarinic agents was examined.
Each value represents the mean ± S.E.M. of four to ﬁve rats.speciﬁc [3H]imidafenacin binding were signiﬁcantly lower in the
submaxillary gland and prostate and higher in the heart than in the
bladder (Table 1). These results demonstrated that [3H]imidafena-
cin preferentially labeled the M1- or M3-dominating tissues of rats
with higher afﬁnity than M2-dominating tissues.
Furthermore, the density of muscarinic receptor subtypes
labeled by [3H]imidafenacin in rat tissues was quantitated using 4-
DAMPmustard, an irreversible inactivating agent of theM3 subtype
(16, 17). The relative densities of M2 and M3 receptors were esti-
mated to be 55% and 45% (bladder), 16% and 84% (submaxillaryBladder
Control 1.40 ± 0.19 411 ± 17
(0.55)4-DAMP mustard 1.64 ± 0.26 228 ± 8***
Submaxillary gland
Control 0.50 ± 0.04 306 ± 12
(0.16)4-DAMP mustard 0.63 ± 1.38 48 ± 21***
Colon
Control 0.90 ± 0.09 389 ± 35
(0.79)4-DAMP mustard 0.96 ± 0.32 306 ± 6**
Heart
Control 4.38 ± 0.60 79 ± 5
(0.99)4-DAMP mustard 3.81 ± 0.52 78 ± 5
The speciﬁc binding of [3H]imidafenacin (0.5e8.0 nM) in the peripheral tissues of
rats was measured in the absence and presence of 1 mM atropine. Values in pa-
rentheses represent the ratio of Bmax values relative to control values. Asterisks
show a signiﬁcant difference from control values, **P < 0.01, ***P < 0.001 (the
Student's t-test). Each value represents the mean ± S.E.M. of four to seven rats.
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(Table 1). These results appear to be consistent with previous
ﬁnding obtained in M1eM5 receptor single knockout mice (22).
In the central nervous tissues of rats, the Kd values of [3H]imi-
dafenacin were roughly similar among the brain regions (cerebral
cortex, hippocampus, corpus striatum, thalamus, pons/medulla
oblongata, and midbrain) except for the cerebellum, which had a
high Kd value (Table 2). The lower afﬁnity of [3H]imidafenacin
binding in the cerebellum may be attributed to the predominant
localization of the M2 subtype, whereas other brain regions con-
tained M1, M2, and M3 subtypes at different ratios (21).
Thus, a tissue differencewas observed in the Kd values of speciﬁc
[3H]imidafenacin binding in the rat, however, the difference in the
Kd values (0.2e0.3 nM) of speciﬁc [3H]NMS binding were negligible
among the peripheral or central nervous tissues of the rat (data not
shown). On the other hand, a strong correlation was noted in Bmax
values in peripheral and central nervous tissues between [3H]imi-
dafenacin and [3H]NMS (Fig. 2), suggesting no difference in
muscarinic receptor densities labeled by these radioligands.
We found that unlabeled imidafenacin and clinically used
antimuscarinic agents (oxybutynin, tolterodine, and solifenacin)
competedwith [3H]imidafenacin for binding sites in the rat bladder
in a concentration-dependent manner (Fig. 4). Kd (1.25 nM) and Ki
(1.25 nM) values for the muscarinic receptor binding afﬁnity of
imidafenacin in the rat bladder approximately corresponded to its
pharmacological potency for the competitive blockade of
carbachol-induced contractions in the isolated bladder tissues of
humans (Kb ¼ 0.59 nM) (28) or the guinea-pig (Kb ¼ 0.81 nM) (7),
thereby indicating that [3H]imidafenacin binding sites correlate
with pharmacological effects of imidafenacin in the bladder. The
results of the present study indicate that [3H]imidafenacin selec-
tively binds to pharmacologically relevant muscarinic receptors in
the bladder and other tissues of the rat. [3H]Quinuclidinyl benzilate
([3H]QNB) or [N-methyl-3H]scopolamine methyl chloride ([3H]
NMS) have commonly been used as radioligands to measure
muscarinic receptor binding in a number of tissues. The advantage
of [3H]imidafenacin over these radioligands may be due to its
greater selectivity to the M3 subtype of muscarinic receptors.
In conclusion, the results of the present study revealed that [3H]
imidafenacin bound to muscarinic receptors with high afﬁnity in
M1- and M3-dominating tissues, which supports a rationale for the
pharmacological usefulness of imidafenacin as a therapeutic agent
of OAB. Thus, [3H]imidafenacin may also be a useful radioligand for
labeling the M3 subtype of muscarinic receptors with high afﬁnity.Conﬂict of interest
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